99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience

Nuclear Medicine Communications

Volumn 29, Issue 12, 2008, Pages 1059-1065

  Gmeiner Stopar, Tanja ^a   Fettich, Jure ^a   Zver, Samo ^a   Mlinaric Rascan, Irena ^a   Hojker, Sergej ^a   Socan, Aljaz ^a   Peitl, Petra Kolenc ^a   Mather, Stephen ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Non Hodgkin's lymphoma; Photoreduction; Radiolabelled antibody

Indexed keywords

CD20 ANTIGEN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TECHNETIUM 99M RITUXIMAB; TECHNETIUM COMPLEX; UNCLASSIFIED DRUG; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PERTECHNETIC ACID TC 99M; POTASSIUM IODIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; RITUXIMAB TC 99M; TECHNETIUM 99M; VINCRISTINE SULFATE; YTTRIUM 90;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER STAGING; CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOLOGY; RADIOIMMUNOASSAY; SCINTISCANNING; STAINING; TISSUE DISTRIBUTION; ANTIGEN EXPRESSION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG PURITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MULTIPLE CYCLE TREATMENT; PHOTOACTIVATION; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; REMISSION; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; TREATMENT PLANNING; TUMOR SCINTISCANNING; ULTRAVIOLET RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BONE MARROW; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOTECHNETIUM COMPOUNDS; RADIOIMMUNODETECTION; STAINING AND LABELING; TISSUE DISTRIBUTION;

EID: 56749170517     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283134d6e     Document Type: Article

References (28)

1. Divgi CR. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology NY 1996; 10:939-958.
2. 99mTc-labelled monoclonal antibodies: a review. Nucl Med Commun 1993; 14:347-359.
3. Mather SJ. Radiolabelled antibodies and peptides. In: Sampson CB, editor. Textbook of radiopharmacy theory and practice. 3rd ed. Amsterdam, The Netherlands: Gordon and Breach Science Publishers; 1990. pp. 63-82.
4. Urbain JLC, Vekemans MCM, Lemieux SK, Cosenza SC, Senadhi VK, Milestone BN, Reddy EP. Nuclear oncology and the imagine concept. Acta Radiol 1997; 38 (Suppl 412):21-28.
5. Granowska M, Britton KE. Radiolabelled monoclonal antibodies in oncology II. Clinical applications in diagnosis. Nucl Med Commun 1991; 12:83-98.
6. Britton KE, Mather SJ, Granowska M. Radiolabelled monoclonal antibodies in oncology III. Radioimmunotherapy. Nucl Med Commun 1991; 12:333-347.
7. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S2-S12.
8. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84:1361-1392.
9. Hoskin PJ, O'Doherty MJ. Lymphoma: diagnosis and management introduction. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S1.
10. Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S65-S81.
11. Hoskin PJ. PET in lymphoma: what are the oncologist's needs? Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S37-S41.
12. Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S56-S64.
13. Sciepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S82-S88.
14. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S42-S55.
15. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S82-S96.
16. 18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol I 2003; 30 (Suppl 1):S97-S105.
17. Al-Nahhas A, Win Z, Al-Sayed Y, Khan S, Singh A, Rubello D, Gishen P. Anatomic and functional imaging in the management of lymphoma. Q J Nucl Med Mol Imaging 2007; 51:251-259.
18. Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S, et al. Chemotherapy for diffuse large-cell lymphoma-rapidily responding patients have more durable remissions. J Clin Oncol 1986; 4:160-164.
19. Mikhael NG, Timoty AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non Hodgkin's lymphoma-comparison with CT. Leuk Leukaemia 2000; 39:543-553.
20. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-174.
21. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102:3514-3520.
22. Manshouri T, Do K, Wang X, Giles FJ, O'Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 10:2507-2513.
23. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Minireview. Brit J Cancer 2003; 89:1389-1394.
24. Johnson PWM, Glennie MJ. Rituximab: mechanisms and application. Brit J Cancer 2001; 85:1619-1623.
25. 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med Mol Imaging 2006; 33:53-59.
26. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134:445-450.
27. Malik E, Juweid ME. Radiotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 1:1507-1529.
28. Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Lewis SM, Bain BJ, Bates I, editors. Dacie and Lewis practical haematology. 9th ed. London: Churchill-Livingstone; 2001. pp. 297-314.